Noticias ARS Pharmaceuticals Inc - SPRY | Acciones NASDAQ

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure...

Form 8-K - Current report

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash...

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand...

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access...

Form 4 - Statement of changes in beneficial ownership of securities

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

JJPK 5 meses hace

Trading like news is eminent

👍️0

stocksrising 5 meses hace

I’m In!! Going long, and selling naked Nov 12.5 puts ( almost $2 per put) GLTA

👍️0

EnchantedTitan62 6 meses hace

Good call on the inhalent, last week FDA approved. Moving up again today. 👍

👍️ 1

JJPK 7 meses hace

Close to 3mil shares traded in the last minute of trading.
Whats Up.??

👍️0

Monksdream 9 meses hace

SPRY under $10

👍️0

erik007tc 10 meses hace

I believe the fda review/approval will be within 6 months.

👍️ 1

Monksdream 10 meses hace

SPRY over $10
Next day settlement begins 5/28 per SEC mandate

👍️0

dodgerdog 10 meses hace

Good News around the corner? 🙂

👍️ 1 🤑 1

gail 1 año hace

ah, should have held, lol

👍️0

gail 1 año hace

not in as i hopped in something else, but watching now.

👍️0

Pt3 1 año hace

It not going up anytime soon but down Fda denied news

i grabbed some today too.

👍️0

makinezmoney 1 año hace

$SPRY:: Fabulous dump down to $2.60 here...............................

OKkkkkkkkkkkkkkkkkkkk.......... lets gooooooooooooooo

GO $SPRY

👍️0

MiamiGent 2 años hace

SPRY Also in ...
ARS PHARMACEUTICALS INC
Pre-market the price per share is $7.85 +$0.10 (1.29%)

https://stockcharts.com/h-sc/ui?s=SPRY

Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $17 Price Target
BENZINGA
8:34 AM ET May-18-2023
Wedbush analyst Andreas Argyrides reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and maintains $17 price target.

👍️0

MiamiGent 2 años hace

SPRY This is spraying profits all over my screen this morning! I have a very green screen! What's going on, I'm trying to glean.

https://stockcharts.com/h-sc/ui?s=SPRY

👍️0

MiamiGent 2 años hace

SPRY $8.32 +$0.28 (+3.483%)
Moving up after waffling this morning
Volume
2,403,836
90 Day Avg. Vol.
927,230

https://stockcharts.com/h-sc/ui?s=SPRY

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

ARS Pharmaceuticals Inc (SPRY)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

SPRY Noticias

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

Form 8-K - Current report

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Form 4 - Statement of changes in beneficial ownership of securities

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

SPRY Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

ARS Pharmaceuticals Inc (SPRY) Noticias

ARS Pharmaceuticals Inc (SPRY)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

SPRY Noticias

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

Form 8-K - Current report

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Form 4 - Statement of changes in beneficial ownership of securities

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

SPRY Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Quitar anuncios